Effect of antidepressant therapy on health care utilization and costs in primary care

Psychiatric Services

Volumn 48, Issue 11, 1997, Pages 1420-1426

  Croghan, Thomas W ^a,b   Lair, Tamra J ^c   Engelhart, Luella ^c   Crown, William E ^c,d   Copley Merriman, Catherine ^a   Melfi, Catherine A ^a,b   Obenchain, Robert L ^a,b   Buesching, Don P ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MEDSTAT GROUP   (United States)

^d BRANDEIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; TRAZODONE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; OUTPATIENT CARE; PHARMACY; PRIMARY MEDICAL CARE; TREATMENT OUTCOME;

EID: 0030681254     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.48.11.1420     Document Type: Article

References (34)

1. VonKorff M, Ormel J, Katon W, et al: Disability and depression among high utilizers of health care: a longitudinal analysis. Archives of General Psychiatry 49:91-100, 1992
2. Regier DA, Hirschfeld MA, Goodwin FK, et al: The NIMH Depression Awareness, Recognition, and Treatment program: structure, aims, and scientific basis. American Journal of Psychiatry 145:1351-1357, 1988
3. Manning W, Wells KB: The effects of psychological distress and psychological well-being on use of medical services. Medical Care 30:541-553, 1992
4. Johnson J, Weissman M, Klerman G: Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 267:1478-1483, 1992
5. Simon G, Ormel J, VonKorff M, et al: Health care costs associated with depressive and anxiety disorders in primary care. American Journal of Psychiatry 152:352-357, 1995
6. Levenson J, Hamer RM, Rossiter LF: Relation of psychopathology in general medical inpatients to use and cost of services. American Journal of Psychiatry 147:1498-1503, 1990
7. Depression Guideline Panel: Depression in Primary Care: Vol 2: Treatment of Major Depression. Clinical Practice Guideline 5. AHCPR pub 93-0550. Rockville, Md, Agency for Health Care Policy and Research, Apr 1993
8. DiMascio A, Weissman MM, Prusoff BA, et al: Differential symptom reduction by drugs and psychotherapy in acute depression. Archives of General Psychiatry 36: 1450-1456, 1979
9. Simon GE, VonKorff M, Barlow W: Health care costs of primary care patients with recognized depression. Archives of General Psychiatry 52:850-856, 1995
10. Newhouse JP: Economists, policy entrepreneurs, and health care reform. Health Affairs 14(1):182-198, 1995
11. LaPierre Y, Bentkover J, Schaimbaum S, et al: Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Canadian Journal of Psychiatry 40:370-377, 1995
12. Revicki DA, Brown RE, Palmer W, et al: Modeling the cost effectiveness of antidepressant treatment in primary care. PharmacoEconomics 8:524-540, 1995
13. LePen C, Levy E, Ravily V, et al: The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs tricyclics. Journal of Affective Disorders 31:1-18, 1994
14. Einarson TR, Arikian S, Sweeney S, et al: A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clinical Therapeutics 17:136-153, 1995
15. Boyer WF, Feighner JP: The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients, in Health Economics of Depression. Edited by Jonsson B, Rosenbaum J. London, Wiley, 1993
16. Jonsson B, Bebbington PE: What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. British Journal of Psychiatry 164: 665-673, 1994
17. Hotopf M, Lewis G, Normand C: Are SSRIs a cost-effective alternative to tricyclics? British Journal of Psychiatry 168:404-409, 1996
18. Sclar DA, Robison LM, Skaer TL, et al: Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clinical Therapeutics 16:715-730, 1994
19. Skaer TL, Sclar DA, Robison LM, et al: Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Current Therapeutic Research 56: 556-567, 1995
20. Simon GE, Wagner EH, VonKorff M: Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. Journal of Clinical Epidemiology 48:363-373, 1995
21. Simon GE, VonKorff M, Heiligenstein JH, et al: Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 275: 1897-1902, 1996
22. Practice guideline for major depressive disorder in adults. American Journal of Psychiatry 150(Apr suppl):1-26, 1993
23. Maj M, Veltro F, Pirozzi R, et al: Pattern of recurrence of illness after recovery of an episode of major depression: a prospective study. American Journal of Psychiatry 149: 795-800, 1992
24. Kupfer DJ, Frank E, Perel MJ, et al: Five-year outcome for maintenance therapies in recurrent depression. Archives of General Psychiatry 49:769-773, 1992
25. Mintz J, Mintz LI, Arruda MJ, et al: Treatments of depression and the functional capacity to work. Archives of General Psychiatry 49:761-768, 1992
26. Iezzoni LI: Severity of illness measures: comments and caveats. Medical Care 28:757-761, 1990
27. Baum KK, Muggeo L, Gable CB, et al: Incorporating severity-of-illness measures into retrospective claims-based cost-effectiveness analyses. Journal of Research in Pharmaceutical Economics 5:59-68, 1993
28. Heckman J: The common structure of statistical models of truncation, sample selection, and limited dependent variables and a simple estimator for such models. Annals of Economic and Social Measurement 5: 475-492, 1976
29. Heckman J: Varieties of selection bias. American Economic Review 80:313-318, 1990
30. Melfi CA, Waldman DM: Limited and discrete dependent variable models: use, applications, and comparisons, in Econometric Modeling in Economic Education Re search. Edited by Becker WE, Walstad WB. Boston, Kluwer-Nijhoff, 1987
31. Katon W, VonKorff M, Lin E, et al: Adequacy and duration of antidepressant treatment in primary care. Medical Care 30:67-76, 1992
32. Berndt ER, Finkelstein SN, Greenburg PE, et al: Workplace performance effects from chronic depression and its treatment. Paper presented at the annual meeting of the American Economic Association, San Francisco, Jan 6-9, 1996
33. Sturm R, Wells KB: How can care for depression become more cost-effective? JAMA 273:51-58, 1995
34. Wells KB, Sturm R: Care for depression in a changing environment. Health Affairs 14(3):78-89, 1995